Apr 7, 2006
Dear Dr. I was wondering if boosting you PI with Norvir only lessens the number of pills needed? Is there any other benefit from the Norvir itself? Thank you
Response from Dr. Young
Thanks for your post.
Part of the reason for this is reduction in the pill count for some PIs; indinavir (Crixivan), saquinavir (Inverase). Other PIs have little change in total pill count with ritonavir-- fosamprenavir's (Lexiva, Telzir) is 4 unboosted, or 2 with 2 ritonavir; atazanavir (Reyataz) daily pill count goes from 2 to 3.
Like any treatment strategy there are strengths and weaknesses-- to me the most important strength is the thought that boosting minimizes the drug resistance consequences of first line treatments. To date, data from patients experiencing first-line boosted PI failure only have shown the M184V mutation-- no measurable resistance to PIs or other nukes have been seen (for the vast majority). This may result in better preservation of future treatment options.
Most importantly, boosting of PIs allows us to consider successful treatment for patients with drug resistance, even multidrug resistance-- using a ritonavir-boosted PI as the anchor to other medications.
Offseting this is the increased risk of having elevations in lipids (cholesterol and triglycerides)-- but, the newer PIs atazanavir and fosamprenavir have shown encouraging results in studies of naive patients.
I hope this helps clarify your question, BY
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.